These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 8163696)

  • 1. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
    Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
    J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
    Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
    Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
    Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
    Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
    Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
    Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
    Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
    Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor.
    Luqmani YA; Ricketts D; Ryall G; Turnbull L; Law M; Coombes RC
    Int J Cancer; 1993 Jun; 54(4):619-23. PubMed ID: 8514453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
    Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
    Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
    Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
    Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
    Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
    Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of the estrogen regulated pS2 protein in mammary tumors.
    Pichon MF; Milgrom E
    Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
    Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
    Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.